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The human endogenous retrovirus K10 (HERV-K10) has been identified in the human genome by its
homology to retroviruses of other vertebrates (M. Ono, T. Yasunaga, T. Miyata, and H. Ushikubo, J. Virol.
60:589–598, 1986). Using PCR amplification, DNA cloning, sequencing, and procaryotic expression, we were
able to demonstrate that HERV-K10 encodes a 73-kDa protein which was processed by a HERV-K10-encoded
protease to yield proteins p22/p26, p30, and p15/16. Analysis of the teratocarcinoma cell line Tera 1 or tumor
tissues by immunoblotting demonstrated that the 80-kDa polyprotein of HERV-K10 gag and a processed
protein of 39 kDa were expressed. In addition, a major protein of 39 kDa and additional species of 30, 22, 19,
and 17 kDa could be detected in the supernatant of Tera 1 cells, suggesting that HERV-K10 Gag proteins are
either secreted or processed to probably incomplete viral particles. In addition, the gag gene of HERV-K10 was
expressed in the baculovirus system. Using this recombinant system to test antisera from patients with
different diseases and healthy individuals, we were able to detect antibodies against the N-terminal part of
HERV-K10 Gag in 2 to 4% of groups of tumor patients with titers ranging between 1:80 and 1:640, while
approximately 0.1 to 0.5% of healthy individuals exhibited antibodies with lower titers. In contrast, patients
with seminoma had antibody titers in the range of 1:2,560 at the time when the tumor was detected.
Immunohistochemistry using specific rabbit sera or monoclonal antibodies against HERV-K10 Gag revealed
that the Gag protein is expressed in the cytoplasm of the tumor cells. Furthermore, an 80-kDa protein
corresponding to the HERV-K10 Gag polyprotein could be detected in tumor biopsies. For the first time, these
data indicate that HERV-K10 Gag proteins are synthesized in seminoma cells and that patients with those
tumors exhibit relatively high antibody titers against Gag. So far, no information on which role HERV-K10
plays in the development of this tumor exists.
Human endogenous retroviruses (HERVs) or human endo-
genous proviral DNAs have been identified in human genomic
DNA by their homology to retroviruses of other vertebrates
(for reviews, see references 9, 11, and 20). The human genome
probably contains numerous copies of proviral DNAs. How-
ever, nothing is known about their function. Because of
different degrees of homology and other features, these provi-
ral DNAs are divided into distinct families. Recently, it was
shown that the proviral element K10 contains an open pol
reading frame (15) as well as open gag and env reading frames
(10, 13) while all other proviral elements exhibit reading
frames with multiple stop codons (9). The semiquantitative
Southern blot analysis of genome copy numbers revealed that
the HERV-K10 element is present in 25 to 30 copies or more
within the genome of human individuals (13, 15). Procaryotic
expression of HERV-K10 gag and prt region demonstrated that
this element encodes a full-length gag homologous 73-kDa
protein and a functional protease which is located in a 21
position relative to the reading frame of gag (13).
Expression of proviral DNA, especially of HERV-K, has
been observed in placental tissue (3), teratocarcinoma cell
lines, and breast cancer cell lines by detection of distinctly sized
transcripts (3, 5, 10, 14). Recently, the expression of HERV-
K10 Gag polyprotein and processed protein in a teratocarci-
noma-derived cell line (GH) has been described previously
(10). Furthermore, the same authors found evidence that
particles related to HERV-K were released from GH cells in
the supernatant (1). Up until now, nothing was known about
the function of HERV-K genes or a possible association
between HERVs and human diseases, although it was specu-
lated that HERV might play a role in autoimmunity (16).
In this study, we were interested in the characterization of
the HERV-K10 gag-encoded proteins and in a possible asso-
ciation of this retroviral element with a human disease. Using
various polyclonal sera and monoclonal antibodies against
different regions of the HERV-K10 Gag polyprotein, we were
able to delineate the processed Gag proteins. Furthermore, by
using the recombinant expression of HERV-K10 gag in the
baculovirus system, antibodies against this protein could be
detected in human individuals.
While healthy donors exhibited reactivity to a very low
percentage (approximately 0.1 to 0.5%), in tumor patients,
depending on the disease, varying percentages of antibody
reactivity in the range between 1 and 4% could be observed.
An exception was patients with testicular tumors, in particular
with seminoma.
A total of 70 to 80% of patients with those tumors exhibited
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high antibody titers to HERV-K10 proteins at the time of the
detection of the tumor. In addition, HERV-K10 Gag proteins
could be identified in seminoma tumor biopsies as well as in a
teratocarcinoma-derived cell line, Tera 1. Furthermore, this
cell line was found to secrete detectable amounts of HERV-
K10 Gag proteins in the supernatant.
MATERIALS AND METHODS
Cells. The cell lines Tera 1 (2) and T47D (6) were obtained from the American
Type Culture Collection. The B95-8 cell line was originally established by
infecting marmoset B lymphocytes with Epstein-Barr virus (12). Tera 1 cells were
maintained in McCoy’s 5a medium supplemented with 10% fetal calf serum, 40
U of penicillin per ml, and 50 mg of streptomycin per ml and were subcultured
once a week. Tera 1 and T47D cells were grown in plastic tissue culture flasks.
Transfer of Tera 1 cells was performed by shaking off the loosely adhering cells
from the culture flasks. For subculturing of T47D cells, a standard trypsin
treatment was used. B95-8 and T47D cells were maintained in RPMI 1640
medium supplemented with 10% fetal calf serum, 40 U of penicillin per ml, 50
mg of streptomycin per ml, 10 U of moronal per ml, and 10 mg of neomycin
sulfate per ml and were subcultured once or twice a week.
SF158 is a continuous insect cell line derived from Spodoptera frugiperda (23).
Cells were maintained as described previously (4). Wild-type baculovirus Autog-
rapha californica nuclear polyhedrosis virus was amplified by infection of SF158
cells. Extracellular virions and viral genomic DNA were prepared as described
previously (23). Escherichia coli BL21-DE-3 has been described previously (22).
Supernatant of cell cultures. Three to four days after subculturing, the culture
supernatants were removed from cells and debris by low-speed centrifugation
(1,500 3 g for 10 min), and the supernatants were filtered through a 0.45-mm-
pore-size disposable filter. The supernatant was centrifuged in a Beckman SW28
rotor at 28,000 rpm for 3 h (100,000 3 g). Subsequently, the pellets were
suspended in sample buffer (125 mM Tris-HCl [pH 6.8], 6%-sodium dodecyl
sulfate [SDS], 10% glycerol, 10% b-mercaptoethanol).
Construction and induction of recombinant procaryotic expression vector and
production of polyclonal rabbit antibodies. The location of all constructs on the
HERV-K10 genome is shown in Fig. 1. The plasmids pKG-P, pKG, and pAUR-1
have been described recently (13). To generate pKP0.8, the EcoRI-MscI
fragment excised from pKG-P was cloned into pATH11 (7) digested with EcoRI
and SmaI. To generate pKN0.7, the EcoRI-EcoRV fragment excised from pKG
was cloned into pATH11 digested with EcoRI and SmaI. The plasmids pKP0.8
and pKN0.7 encode fusion proteins containing 37 kDa of the amino terminus of
the anthranilate synthetase (TrpE) of E. coli and the C-terminal (pKP0.8) or the
N-terminal (pKN0.7) part of the HERV-K10 Gag protein.
E. coli BL21-DE-3 was transformed with the plasmids, and induction of the
fusion proteins was carried out as described previously (7). The fusion proteins
were used to produce polyclonal antisera. In this purpose, they were purified by
electrophoresis in SDS–10% polyacrylamide gels and used to immunize rabbits
as described previously (4, 13). The rabbit sera raised against the fusion proteins
encoded by the plasmids pKG, pKN0.7, and pKP0.8 are referred to as serum no.
6897 (anti-gag serum), serum no. 266 (anti-N-terminal part serum), and serum
no. 8037 (anti C-terminal part serum).
Construction of baculovirus transfer vector and generation of recombinant
baculoviruses. An AatII-HindIII fragment excised from the vector pUC19 was
cloned into pKG digested with AatII and HindIII. The resulting plasmid,
pUCGAG, was digested with KpnI. After isolation of a KpnI-resistant gag-
specific fragment, it was cloned in a KpnI-digested pUC19 vector. From this
plasmid, designated pUC-GAG*, a SmaI-MscI fragment was isolated and cloned
into SmaI-digested baculovirus transfer vector pAC409. The resulting plasmid,
called pACGAG, was used to generate the recombinant baculovirus. Further-
more, the insect cell line SF158 was cotransfected with Autographa californica
nuclear polyhedrosis virus genomic DNA and the recombinant transfer vector
pACGAG as described recently (4).
Immunofluorescence. Indirect immunofluorescence for the determination of
antibody titers against HERV-K10 Gag was carried out as follows. SF158 cells in
the logarithmic growth phase were infected with pACGAG. Wild-type baculo-
virus-infected cells served as a control. Cells were harvested 42 h postinfection
and mixed with uninfected cells at a ratio of 1:40. Cover slides were coated with
the cell mixture and fixed at 2208C for 10 min in acetone. The cells were
incubated for 45 min with human or rabbit sera diluted in phosphate-buffered
saline (PBS) and stained by indirect immunofluorescence with fluorescein
isothiocyanate-conjugated goat anti-human immunoglobulin G (IgG) or goat
anti-rabbit IgG diluted 1:50, respectively.
Immunoblots. Proteins were separated on SDS-polyacrylamide gels (SDS-
polyacrylamide gel electrophoresis [PAGE]) and electrophoretically transferred
to Immobilon membranes (Millipore Corp.) (24). The blots were incubated with
rabbit antisera at a dilution of 1:200 and then stained indirectly by using
peroxidase-conjugated goat anti-rabbit antibodies. When the staining was per-
formed by the enhanced chemiluminescence technique (Amersham), nitrocellu-
lose membrane was used for the electrophoretic transfer.
Immunoblotting analysis of tumor biopsies. Tissue samples stored at 2708C
were homogenized on ice in sample buffer. After incubation at 958C for 10 min
and centrifugation for 10 min at 15,000 3 g, the supernatant was analyzed by
SDS-PAGE and immunoblotting as reported recently (18).
Competition assays. In competition fluorescence assays, the antisera used for
staining were preincubated with 2 mg of isolated fusion protein or anthranilate
synthetase protein per ml overnight at 48C. In competition immunoblot assays,
the preincubation was carried out in 10% nonfat milk.
Production of monoclonal antibodies. The plasmids pAUR-1 and pKP0.8
encoding the central and the N-terminal parts of the HERV-K10 Gag protein,
respectively (Fig. 1), were used to produce monoclonal antibodies. The fusion
proteins were isolated as described above. Approximately 20 mg of SDS-PAGE-
purified fusion protein dissolved in 200 ml of PBS and emulsified with 200 ml
of Freund’s complete adjuvant was injected intraperitoneally and subcutaneous-
ly into Lou/c rats (E20, Bazin JIM 112:53). On day 21, the procedure was
repeated with Freund’s incomplete adjuvant. Three days before fusion, a final
boost without adjuvant was given intraperitoneally. Fusion of the myeloma
P3X63Ag8.653 with the rat immune spleen cells was performed according to the
general procedure described in reference 8. Hybridoma supernatants were tested
in a solid-phase immunoassay with bacterial extract from either E. coli expressing
the parental nonfusion TrpE protein or HERV-K10 Gag fusion protein.
Polystyrene microtiter plates (Greiner, Frickenhausen, Germany) were coated
with the crude E. coli extracts diluted 1:200 in carbonate-bicarbonate buffer (50
mM, pH 9.5), as determined with anti-TrpE monoclonal antibody (M1). The
wells were blocked with PBS containing 1% nonfat milk (Fink, Herrenburg,
Germany). Culture supernatants were incubated for 1 h, and bound rat mono-
clonal antibodies were detected with goat anti-rat IgG coupled with horseradish
peroxidase (Dianova, Hamburg, Germany), with O-phenylenediamine (Sigma,
Deisenhofen, Germany) as substrate. Antibody-producing hybridomas which
reacted positively with the HERV-K10 Gag fusion protein and negatively with
nonfusion TrpE protein were tested against fusion protein of the C-terminal or
middle part of the HERV-K10 Gag and cloned at least twice by limiting dilution.
The immunoglobulin type was determined in a solid-phase enzyme-linked
immunosorbent assay with mouse anti-rat antibodies as capture and biotinylated
monoclonal mouse anti-rat Ig class (anti-IgM, Zymed) and anti-IgG subclass
antibodies as indicators (21). The positive clones were confirmed by immuno-
fluorescence with full-length Gag protein expressed in SF158 insect cells, as
described above. Unspecific binding was blocked by PBS containing 5% fetal calf
serum. Hybridoma supernatant was incubated for 1 h, and bound rat monoclonal
antibodies were detected by goat anti-rat IgG-fluorescein isothiocyanate.
FIG. 1. Restriction map according to references 13 and 15 and open reading
frames of the HERV genome (HERV-K10). Shown is a schematic representa-
tion of the plasmids which were used for procaryotic expression (pKG-P, pKG),
for eucaryotic expression (pACGAG), for raising polyclonal rabbit sera (pKG,
pAUR-1, pKN0.7, pKP0.8), and for generating monoclonal antibodies (pAUR-1,
pKP0.8). LTR, long terminal repeat; ORF, open reading frame.
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Immunohistochemistry. Formalin-fixed, paraffin-embedded testicular tumor
tissue or, as a control, Tera 1 cells were sectioned at 4 mm, deparaffinized, rinsed
in PBS, and incubated for 30 min in hydrogen peroxide (0.6% in methanol) and
rinsed again in PBS. The tissue sections were pretreated in citrate buffer (0.01 M;
pH 6.0) in a microwave oven for 5 min at 600 W and 5 min at 450 W. After being
cooled to room temperature, the sections were incubated with swine serum for
20 min. For immunostaining, the slides were incubated at room temperature with
the rabbit anti HERV-K10 Gag serum or, as a control, preimmune serum diluted
1:40 for 1 to 2 h and then incubated with biotin-conjugated swine anti-rabbit
antibodies, diluted 1:200 (DAKO), for 30 min and with avidin-biotin complex,
diluted 1:100 (DAKO), for 30 min and developed with diaminobenzidine. After
each incubation step, the slides were rinsed in PBS for 5 min.
RESULTS
Characterization of the HERV-K10 Gag proteins. Recently,
we reported that HERV-K10 encodes a full-length gag homol-
ogous 73-kDa protein and a functional protease. Furthermore,
we were able to demonstrate that HERV-K10 Gag polyprotein
was specifically processed by the HERV-K10-encoded pro-
tease which exhibits features of an aspartate-type protease (13,
19).
In order to distinguish the processed HERV-K10 Gag
proteins from the 73-kDa Gag polyprotein, a DNA fragment
containing the entire gag reading frame and the adjacent
protease region construct pKG-P (Fig. 1) was inserted into the
expression vector pATH11 and expressed in E. coli BL21-DE-3
as described recently (13).
Protein extracts were analyzed by protein immunoblot with
monoclonal antibodies or polyclonal rabbit sera directed
against different parts of the HERV-K10 Gag polyprotein as
shown in Fig. 2.
With the polyclonal rabbit serum, three dominant protein
bands with molecular masses of 30, 26, and 22 kDa could be
observed while a monoclonal antibody directed against the
C-terminal part of HERV-K10 Gag reacted predominantly
with two proteins of 15 and 16 kDa. A polyclonal rabbit serum
directed against 228 amino acids of the N-terminal part
exhibited the strongest reaction against the 22-kDa protein. In
the reaction of a monoclonal antibody directed against the
central part of HERV-K10 Gag, the 30-kDa protein was found
to exhibit strong activity while a protein band of 26 kDa
reacted to a smaller extent. Additional protein bands on the
upper part of the gel with extremely strong reactions presum-
ably represent the partially processed HERV-K10 Gag poly-
protein. Several protein bands in the lower part of the gel
might represent degradation products of HERV-K10 Gag due
to the presence of bacterial proteases. The data obtained from
the experiments whose results are shown in Fig. 2 clearly locate
the 15- and 16-kDa proteins at the C terminus. Located next to
these proteins is the 30-kDa protein, while good evidence
exists for the location of the 22-kDa protein at the N terminus.
Finally, the 26-kDa protein seems to be encoded by a central
region between the 22- and the 30-kDa proteins. A tentative
model for the processing of the HERV-K10 Gag protein is
shown in Fig. 3A.
Eucaryotic expression of HERV-K10 Gag. Recently, the
expression of HERV-K10 Gag protein in the human terato-
carcinoma cell line GH was reported (1). In order to study the
expression and the processing of the Gag polyprotein in more
detail, protein extracts from the teratocarcinoma cell line Tera
1 and the 100,000 3 g pellet of the supernatant of this cell line
were analyzed by immunoblotting with different specific rabbit
anti-HERV-K10 Gag sera or monoclonal antibodies. Repre-
sentative results are shown in Fig. 4. The investigation of Tera
1 cell extracts with a serum against the entire Gag polyprotein
(serum no. 6897) revealed the existence of an 80-kDa protein
which seems to correspond to the full-length Gag polyprotein.
Further protein bands of approximately 70, 53, and 39 kDa
could be identified, representing partially processed Gag pro-
teins. By analyzing the 100,000 3 g pellet of the supernatant
from Tera 1 cells by the same method, additional protein bands
of 30, 22, 19, and 17 kDa could be observed. The correspond-
ing material from HERV-K10-negative B95-8 cells (New
World monkey) or T47D cells served as a control.
By analyzing the 100,000 3 g pellet by using rabbit antisera
against different parts of the Gag polyprotein, it was possible to
construct a tentative order of processed HERV-K10 Gag
proteins expressed in the cell line Tera 1 (Fig. 3B). For
example, a 15-kDa protein was recognized only by the serum
against the C terminus while a 30-kDa protein reacted most
dominantly with the serum directed against the middle part of
HERV-K10 Gag. In addition, an 18-kDa protein was identified
by the serum against the N terminus.
At the present time, we have no definite information about
in which order the 22-, 19-, and 17-kDa proteins are located on
the HERV-K10 gag gene. These proteins are detected by the
antiserum against the middle part of gag. Only the 22-kDa
protein exhibits a weak reaction with the N-terminally directed
serum. Concerning the C-terminal part of HERV-K10 gag, the
FIG. 2. Procaryotic expression and immunoblot analysis of protein products
by the construct pKG containing the gag-homologous region of HERV-K10,
pKG-P containing the putative protease gene in addition to the gag-homologous
region, or the vector pATH alone as described in Materials and Methods. Total
bacterial protein (5 mg) was subjected to SDS–15% PAGE. After blotting, the
filter membranes were probed with an anti-Gag polyclonal rabbit serum, a
polyclonal rabbit serum raised against the N-terminal part (pKN0.7) of the Gag
protein, and monoclonal antibodies generated against the middle part (pAUR-1)
or against the C-terminal part (pKP0.8) of the Gag protein. The apparent
molecular masses were calculated from comigrating molecular mass standards
and are given in kilodaltons.
FIG. 3. Tentative location of the processed HERV-K10 Gag proteins: pro-
caryotic expressed Gag protein in E. coli (A) and Gag protein expressed in Tera
1 cells (B).
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procaryotic expression in E. coli and the expression of HERV-
K10 gag in Tera 1 cells revealed good correspondence.
Analysis of human antibodies reacting with recombinant
HERV-K10 Gag protein. To investigate a possible role of
HERV-K10 expression in the development of pathogenic
events in humans, we expressed HERV-K10 Gag in the
baculovirus system and established a system for testing human
antibodies by immunofluorescence as described in Materials
and Methods.
For analyzing human sera, insect cells expressing HERV-
K10 gag were diluted 1:40 with uninfected cells to reach a
concentration of 5 to 15 Gag-positive cells per visual field in
order to avoid an overrepresentation of Gag antigen. Human
sera were screened at an initial concentration of 1:40 and
titrated in twofold dilutions. A variety of healthy individuals as
well as patients with different diseases as indicated in Tables 1
and 2 were investigated. While approximately 0.4% of healthy
individuals exhibit low antibody titers, patients with autoim-
mune diseases, human immunodeficiency virus infection, or
different tumors exhibited antibodies in 2 to 4% of the cases.
In contrast, patients with seminoma, a particular form of
testicular tumor, had high antibody titers to Gag proteins. A
total of 10 of 14 serum samples from seminoma patients with
primary tumors tested within 6 weeks after the beginning of
therapy had titers against Gag of up to 1:2,560 and in one case
up to 1:20,480 (Table 3). In addition, 4 seminoma patients with
recidivous tumors exhibited antibodies against Gag while 4
patients with fresh primary tumors and 17 seminoma patients
after a longer time of therapy showed no antibody reactivity
against HERV-K10 Gag. Of a total of 31 seminoma patients,
45% had HERV-K10 Gag antibodies regardless of whether
they had freshly detected tumors or not. In one case, three
consecutive serum samples of one patient were available.
When these sera were tested, the serum taken 36 months
before tumor diagnosis was HERV-K10 Gag antibody negative
while the serum taken at the time of tumor detection showed
a titer of 1:2,560. Six months after onset of therapy, a titer of
1:40 could be determined.
The specificity of the immunofluorescence reaction was
FIG. 4. Immunoblot analysis of cellular extracts and supernatants (SN), as
described in Materials and Methods, of the cell line Tera 1 with polyclonal
antisera against HERV-K10 Gag. The cell lines Tera 1, a teratocarcinoma cell
line, and T47D, a mammocarcinoma cell line, were obtained from the American
Type Culture Collection. B95-8 is a HERV-K10-negative New World monkey
cell line. To yield the supernatant extracts (SN), the culture supernatants were
removed from cells and debris by low-speed centrifugation and were filtered
through a 0.45-mm-pore-size disposable filter. Subsequently, the supernatant was
centrifuged in a Beckman SW28 rotor at 28,000 rpm for 3 h (100,000 3 g). The
resulting pellets were resuspended in sample buffer, and 1 mg was subjected to
SDS–15% PAGE. After blotting, the filter membranes were probed either with
rabbit sera directed against the middle part (pAUR-1), the C-terminal part
(pKP0.8), or the N-terminal part (pKN0.7) or with the entire Gag protein (total,
pKG) as indicated. Controls were performed by using preimmune serum. The
apparent molecular masses were calculated from comigrating molecular mass
standards and are given in kilodaltons.
TABLE 1. Determination of antibodies against HERV-K10 Gag in
sera from healthy individuals or patients with nontumor diseases
Diagnosis No. of serumsamples tested
No. of positive
serum samples Titer %
Autoimmune diseasea 153 2 1:40 1.3
1:40
Immunosuppression 53 0
HIVb positive 113 3 1:160
1:160 2.7
1:80
HIV negative 106 1 1:320 0.9
Controls (students
and hospital staff)
233 1 1:40 0.4
Total 658 7 1.0
a Lupus erythematosus, multiple sclerosis, mixed connective tissue disease,
scleroderma, Sharp syndrome, Sjo¨gren’s syndrome, Cogan syndrome, arthritis.
b HIV, human immunodeficiency virus.
TABLE 2. Determination of antibodies against HERV-K10
Gag in sera from patients with tumor diseases
Diagnosisa
No. of serum
samples
tested
No. of posi-
tive serum
samples
Titer %
Mammary carcinoma 103 3 1:80
1:80 2.9
1:160
Brain tumor 128 4 1:40
1:80 3.6
1:320
1:320
AML 59
Leukemia 7 1:80
ALL 81 3 1:40 3.7
CML 8 1:80
CLL 14
Non-Hodgkin lym-
phoma
63 3 1:2,560
1:320 4.8
1:640
Hodgkin’s disease 164 3 1:80
1:40 1.8
1:80
Burkitt’s lymphoma 8 0
Nasopharyngeal car-
cinoma
6 0
Hairy leukoplakia 1 0
Colon carcinoma 3 0
Lymphoma 88 2 1:40 2.3
1:640
Tumor disease 341 10 1:320 1:320
1:160 1:80
1:40 1:160 2.9
1:320 1:40
1:160 1:40
Testicular tumorsb 17
Teratoma 9 1 1:160 11
Seminoma 31 14 —c 45
Total 1,131 43 3.9
a AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia;
CML, chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia.
bMixed tumors, Leyding cell tumors, embryonal carcinoma, urothelial carci-
noma.
c See Table 3.
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proven by competition experiments using different recombi-
nant fusion proteins of HERV-K10 Gag (pKG, pAUR-1,
pKP0.8, pKN0.7) as demonstrated in Fig. 1. The results in
Table 4 clearly indicate that the Gag fusion protein covering
the N-terminal part or the entire gag region of HERV-K10 gag
completely inhibited binding of the serum antibodies to the
Gag protein while fusion proteins from the middle or C-
terminal part as well as the bacterial part of the fusion protein
(TrpE) achieved no or only minor effect. These data provide
evidence that the major epitopes recognized by positive human
sera are located probably within the 54 N-terminal amino acids
of Gag while no reactivity against the central part of Gag was
detectable.
Expression of HERV-K10 Gag protein in tumor biopsies.
The presence of antibodies against HERV-K10 Gag predom-
inantly in patients with seminoma raised the possibility that
this protein might be expressed in the tumor itself. In order to
prove this hypothesis, tumor biopsies from patients with anti-
body titers against HERV-K10 Gag were tested by immuno-
histochemistry and immunoblotting analysis for the expression
of HERV-K10 Gag.
Sections of formalin-fixed paraffin wax blocks from a semi-
noma mixed with embryonal carcinoma cells or a pure semi-
noma were stained by using a rabbit antiserum (serum no.
6897) directed against the entire HERV-K10 Gag as described
in Materials and Methods. The results as shown in Fig. 5B and
C indicate that Gag-related proteins could be detected in the
form of clusters concentrated within the cytoplasm of the
tumor cells. In contrast, in the surrounding tissue or in tissue of
healthy testes no positive reaction could be found. Used as
positive controls were acetone-fixed insect cells expressing
recombinant HERV-K10 gag (data not shown) or formalin-
fixed and paraffin wax-embedded Tera 1 cells in which positive
reactive material was found predominantly concentrated in the
cytoplasm (Fig. 5A).
From a few biopsies, frozen material was available. These
tissues were processed and analyzed by immunoblotting with
rabbit anti-HERV-K10 Gag serum (serum no. 6897) or mono-
clonal antibodies to Gag as described in Materials and Meth-
ods. Representative results are shown in Fig. 6. The rabbit
anti-Gag serum specifically recognizes a protein band of 80
kDa which presumably represents the Gag polyprotein which
was predominantly found in biopsy 1, while in biopsies 3, 4, 8,
and 5 only a weak reaction could be observed (Fig. 6A). By
using a monoclonal antibody directed against the middle part
of HERV-K10 Gag, the 80-kDa protein band was clearly
detected in biopsies 1, 3, 4, and 8 (Fig. 6B).
Several background bands with a molecular mass of about 50
kDa were found by using both antisera or monoclonal anti-
bodies. At the present time, nothing is known about the nature
of those 50-kDa proteins. In Table 5, the biopsies analyzed in
Fig. 6 are summarized. The numbering of biopsies corresponds
to the numbers given in Table 5. In competition experiments
using full-length recombinant fusion protein of HERV-K10
Gag (pKG) for preincubation of the specific rabbit serum (no.
6897) or monoclonal antibodies, the binding of specific anti-
bodies to the 80-kDa protein from biopsies 1 and 8 could be
abolished (17).
It should be mentioned that in the E. coli expression system
the monoclonal antibody directed against the middle part of
HERV-K10 Gag as well as the monoclonal antibody against
the C-terminal part recognized the processed Gag proteins
only but did not react reproducibly with the 80-kDa Gag
polyprotein (Fig. 2). One possible explanation for this different
reaction pattern could be that the relevant epitopes are not
accessible for the described monoclonal antibodies on the
Gag-TrpE fusion protein because of an overload by other
bacterial proteins.
TABLE 3. Determination of antibodies against HERV-K10
Gag in sera from patients with seminoma
Diagnosis
No. of positive serum
samples/no. of serum
samples tested
Titer %
Primary seminoma 10/14a 1:2,560
1:160
1:640
1:640
1:40
1:20,480
1:160 78
1:2,560
1:2,560
1:320
Seminoma relapse 4/4a 1:80
1:160
1:160
1:640
Seminoma 0/17b
Total 14/31 45
a Sera tested within 6 weeks after start of therapy (half-life of IgG 5 20 to 23
days).
b Sera tested months or years after therapy.
TABLE 4. Inhibition of HERV-K10 immunofluorescencea
Serum
Inhibition by:
pATH 11
(vector)
pKG
(total)
pAUR-1
(middle)
pKP0.8 (C
terminus)
pKN0.7 (N
terminus)
IF without
competition
1. Human 1 (1) 0 1 1 0 1
2. Human 11 0 (1) 1 0 11
3. Human 1 0 (1) (1) 0 11
4. Human 11 0 11 11 0 11
5. Human 1 (1) 0 1 1 0 1
6. Human 1 0 (1) (1) 0 1
7. Human 1 0 1 1 0 1
8. Human 1 0 (1) (1) 0 1
Rabbit anti-HERV-K10 Gag 11 0 11 11 111 111
a Prior to immunofluorescence (IF), sera were preincubated with isolated fusion proteins encoded by constructs as indicated and described in Materials and Methods.
(1), a weak positive reaction.
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FIG. 5. Immunohistochemistry analysis of Tera 1 cells (A) or of biopsies from patients with a seminoma and a combined embryo carcinoma (B) or with seminoma
(C). Sections of formalin-fixed paraffin-embedded tumor tissue or Tera 1 cells were incubated with rabbit anti-HERV-K10 Gag serum no. 6897 followed by
biotin-conjugated swine anti-rabbit serum and incubation with an avidin-biotin complex. The immunostaining was performed with diaminobenzidine.
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DISCUSSION
Recently, the expression of HERV-K10 gag-encoded protein
in E. coli or in a human teratocarcinoma cell line has been
reported (1, 10, 13). In addition, it was shown that HERV-K10
encodes a functional protease of the aspartate type (13).
In order to study the processing of HERV-K10 Gag polypro-
tein in more detail, antisera or monoclonal antibodies specif-
ically directed against the N or C terminus or against the
central part of HERV-K10 Gag were generated. By using these
antibodies to analyze procaryotic expression or expression in
Tera 1 cells, it was possible to determine the tentative se-
quence of the processed Gag proteins. Both procaryotic and
eucaryotic expression revealed that at the C-terminal end of
the Gag polyprotein is an approximately 15-kDa protein
followed by a 30-kDa protein. By analyzing the HERV-K10
expression in Tera 1 cells, an 18-kDa protein could clearly be
determined to be located at the N-terminal end of HERV-K10
Gag, while the exact localization of three proteins of 22, 19,
and 17 kDa derived from the central part of Gag could not
definitively be assigned. Similarly, in E. coli the exact order of
the 26- and 22-kDa proteins derived from the N terminus
cannot be determined yet by the methods used for these
experiments.
The detection of processed HERV-K10 Gag proteins in the
100,0003 g pellet of the supernatant from Tera 1 cells suggests
that those proteins are secreted. These data are supported by
recent reports indicating particle formation from human ter-
atocarcinoma cells (1). At the present time, no information is
available as to whether those particles contain HERV-K10
RNA and whether they constitute infectious particles.
In order to search for a potential pathophysiological role of
HERV-K10, the gag region was expressed in the baculovirus
system. The recombinant protein was utilized to screen human
sera for antibody reactivity by employing the immunofluores-
cence technique. While the expression of gag-specific antibod-
ies in healthy individuals is a rare event (only 1 case of 233
tested serum samples with a titer of 1:40), 2 to 4% of patients
with various diseases or tumors exhibited antibody titers in the
range between 1:40 and 1:640. One exception was found in a
patient with a non-Hodgkin lymphoma with a titer of 1:2,560.
In contrast, 45% of patients with seminoma revealed antibody
titers against HERV-K10 Gag ranging between 1:40 and
1:20,480. An even higher percentage (78%) of patients with
seminoma exhibited antibody titers at the time of diagnosis or
when recidivous tumors occurred. This observation was con-
firmed by the analysis of three follow-up serum samples from
one patient which indeed only contained a high amount of
antibodies at the time of tumor detection and before therapy.
The specific epitopes reacting in the immunofluorescence
test were narrowed down to 54 amino acids at the N-terminal
part of HERV-K10 gag. By computer analysis using the
PALIGN program of PC/GENE (IntelliGenetics, Inc., Moun-
FIG. 6. Immunoblot analysis of testicular tumor biopsies. Tissue samples were homogenized on ice in sample buffer. After incubation at 958C for 10 min and
centrifugation for 10 min at 15,000 3 g, the supernatant was analyzed (lanes 1 to 8). From every material, 15 mg of protein was subjected to SDS–12.5% PAGE. After
blotting, the membranes were probed with rabbit serum no. 6897 directed against the entire Gag protein (pKG) (A) or with monoclonal antibodies directed against
the middle part of the Gag protein (pAUR-1) (B). Tera 1 cells served as positive controls, and B95-8 cells served as negative controls. Numbers at left of panels,
molecular masses in kilodaltons. Lane numbers correspond to numbering of biopsies as given in Table 5.
TABLE 5. Characterization of patients by immunoblotting, immunohistochemistry, and antibody reaction against HERV-K10 Gag
Registration no. Clinical diagnosis Protein immunoblot Immunohistochemistry Antibody titer
1 Seminoma Positive Positive in compartments (11) 1:160
2 Teratoma Negative Negative NDa
3 Seminoma Positive (MAbb) Negative ND
4 Seminoma Positive Positive (11) ND
5 Mixed seminoma Positive Negative (material in bad condition) ND
6 Surrounding tissue Negative Negative
7 Surrounding tissue Negative Negative ND
8 Seminoma Positive Frozen section positive (1) ND
Fixed tissue negative
9, patient P Mixed seminoma ND Positive (111) 1:2,560
10, patient Z Seminoma ND Positive (11) 1:2,560
11, patient B Mixed seminoma ND Positive (11) ND
a ND, not determined.
bMAb, monoclonal antibody.
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tain View, Calif.), these amino acids showed a minor homology
of 5 amino acids to the gag genes of Mason-Pfizer monkey
virus, Jaagsiekte sheep retrovirus, and squirrel monkey retro-
virus but no homology to other known viruses or cellular genes.
Therefore, we believe that the antibodies found among healthy
individuals and patients are specifically induced by the expres-
sion of HERV-K10 Gag.
In order to test the hypothesis that the Gag-specific antibod-
ies were indeed due to the presence of antigen, the expression
of HERV-K10 Gag protein in biopsy material of patients with
seminoma and related tumors was analyzed either by immu-
nohistochemistry or by immunoblotting. The use of both
methods demonstrates that in seminoma tumor biopsies from
seropositive patients as well as for seminoma patients from
whom no antisera were available, protein with HERV-K10
Gag reactivity could be reproducibly identified. To our knowl-
edge, this is the first demonstration that HERV-K10 Gag
proteins are synthesized in seminoma tumor cells and that a
high percentage of patients with those tumors exhibit elevated
antibody titers against Gag. Furthermore, the data obtained
with the follow-up sera of one patient might suggest that
antibodies in seminoma tumor patients have diagnostic and
prognostic value. At the present time, no information exists on
which role HERV-K10 plays in the development of this tumor.
Furthermore, we have no indication whether HERV-K10 gag
or other proviral genes are expressed in other tumors of germ
line origin. These questions remain to be elucidated in further
investigations.
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